The discovery of tumor tropism of stem cells revealed the intimate relationship between stem cells and tumor cells, but the functional role of stem cells in tumorigenesis is poorly understood. To investigate embryonic stem cell (ESC) and tumor cell interactions, we co-cultured mouse ESCs with mouse melanoma B16-F10 cells or mouse pancreatic tumor Pan02 cells, and found that ESCs significantly inhibited tumor cell proliferation. Coculture of ESCs and tumor cells resulted in significant inhibition of tumorigenesis in vivo. Histological analyses indicated that ESCs encircled apoptotic tumor cells. We carried out time course RNA-Seq analyses of ESC and tumor cell co-cultures, and identified Fas/FasL signaling as a major pathway involved in ESC-mediated apoptosis of tumor cells. We further generated FADD-deficient tumor cells by CRISPR/Cas9-mediated gene editing, and demonstrated that FADD-deficient tumor cells were obviously resistant to ESC-mediated inhibition of tumor cell proliferation. Our results indicate the Fas/FasL signaling pathway plays a critical role in ESCs-mediated tumoricidal activity.
Introduction
Malignant tumors are a major public health problem worldwide. One in four deaths in the United States is due to cancer. According to the American Cancer Society, 1,665,540 new cancer cases and 585,720 cancer deaths are projected to occur in the United States in 2014. 1 However, there is no 100% effective treatment for cancer. This is also the era of stem cell biology. The potential applications of stem cells in the field of clinical treatments and the relationships between stem cells and tumor cells are current hot topics. 2 Stem cells from a variety of organs might have the potential to be used for therapy. 3 For example, hematopoietic stem cells have already been used extensively in therapeutic settings. 4 An experimental observation revealed that neural stem cells migrate toward tumor cells and even track tumor cells across a brain hemisphere or through systemic blood circulation. [5] [6] [7] Other kinds of stem cells, such as mesenchymal stem cells, may have the ability to induce apoptosis pathways in tumor cells. [8] [9] [10] [11] [12] Therefore, we hypothesized that embryonic stem cells (ESCs) may have similar features and interact with tumor cells. The potential clinical application of ESCs might be a new rational strategy for stem cell-mediated cancer therapy.
Material and Methods

Mice and cell lines
Female nude mice, 5-6 weeks old, were purchased from Vital River Laboratory Animal Technology Co. Ltd (Beijing, China). Animal experiments were approved by the Animal Care and Use Committee of Peking Union Medical College (PUMC).
Murine cell lines B16-F10 (melanoma) and Pan02 (pancreatic cancer) and FBs were purchased from the American Type Culture Collection. The murine ESC line was obtained from Yue Huang's laboratory at PUMC. B16-F10 and Pan02 cells were also modified to express red fluorescent protein.
Cell culture and transfection
FBs, and B16-F10 and Pan02 cells were grown in 1% serumcontaining medium. ESCs were cultured in ESC medium. 13, 14 In the experiments of validating the importance of Fas-FasL signaling pathway, tumor cells were incubated with ESCs in the presence or absence of FasL-inhibitor (AF-016; Kamiya Biomedical Co., Seattle WA; 20 lg/ml). FADD (1,861 bp) is the key adaptor protein transmitting apoptotic signals mediated by the main death receptors. 15, 16 To generate a CRISPR/ 
Real-time RT-PCR
Total RNA was purified from B16-F10 cells and ESCs with Trizol (Invitrogen, Waltham, Massachusetts, USA). Expression of apoptosis-related genes and GAPDH (control) was analyzed by real-time PCR. Reverse transcription was performed using an iScript cDNA Synthesis Kit (Bio-Rad, Hercules, California, USA) with oligo-dT primers. PCR was performed using a Bio-Rad iQ5 Multicolor Real-Time PCR Detection System with SYBR Green (Bio-Rad) and ROX (Bio-Rad) as the reference dye. PCR primers were obtained from the Harvard Primer Bank (http://pga.mgh.harvard.edu/ primerbank/).
Immunoblotting
After separation, ESCs and B16-F10 cells were lysed for 30 min on ice in lysis buffer, followed by centrifugation at 12,000g at 48C for 10 min. After centrifugation, supernatants were boiled in SDS loading buffer. [17] [18] [19] [20] In the analysis, only genes with a fold change of more than two in different data sets were applied to pathway analysis. Fisher's exact test was used to determine the statistical significance of each pathway. 21 The pathway analysis was based on fold changes calculated by Partek software. Many networks were constructed to visualize the pathways. We validated fold-change data based on networks in the RPKM data file to exclude false positives. Different gene expression between cells in different groups was assessed using t-tests by R analysis (http://www.r-project.org/). The significance of differential gene expression data was considered at p <0.05.
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Apoptosis analysis
At various coculture days, B16-F10 cells (no Ds-Red) were harvested and applied to a BD Pharmingen TM FITC Annexin V Apoptosis Detection Kit I (Product number 556547) to detect cell apoptosis. FITC Annexin V staining was analyzed by a BD Accuri C6.
Statistical analysis
Results are expressed as mean values 6 standard error of the mean and interpreted by repeated-measure analysis of (Figs. 1b and 1d ). This inhibition effect did not disappear until ESCs were only 1/20 of B16-F10 cells (Fig. 1) . When we changed B16-F10 cells to Pan02 or other tumor cells, the same phenomenon was seen (Fig. S1) . To better show that ESCs reduced the lethality of tumor cells, the size of subcutaneous tumors was measured. Compared to control groups, tumors in experimental groups were growing slower and smaller at various ratios (p < 0.05; Fig. 2b ).
To demonstrate that a single ESC distributing in the main tumor mass, pathological analysis of the subcutaneous tumors was performed. Hematoxylin-eosin (H&E) staining and multiplex immunohistochemistry were used to analysis the pathology of tumors. 23 Because the tumor cells expressed ds-Red and ESCs express OCT4 specifically, [24] [25] [26] we used dsRed to mark tumor cells and GFP to mark OCT4 in ESCs. Double immunofluorescence was performed for ds-Red and GFP with DAPI staining, which was quantified by FV10-ASW 3.1 Viewer (Media Cybernetics). 27, 28 According to the histochemical analysis, ESCs surrounded B16-F10 cells in tumors in vivo ( Fig. 2c and 2d ). In addition, B16-F10 cells did not appear to be quiescent or immutable, because they synthesized substantially less melanin in experimental groups than control groups (Fig. 2c) .
RNA-Seq results shows that ESCs mediate apoptosis of tumor cells
A suspension of 1 3 10 5 dissociated ESCs mixed with B16-F10 cells (1:1 ratio) were seeded into each well of six-well plates on Day 0. They were co-cultured in ESC medium mixed with 1% serum-containing medium (1:1 ratio). Cells were collected on days 0 (just prior to cocultivation), 3 and 5 after the cocultivation and separated by detecting the red fluorescence of B16-F10 cells in a fluorescence-activated cell sorter.
Next generation sequencing by RNA-Seq was used to provide the first unbiased comprehensive comparison of gene expression between B16-F10 cells and ESCs. After obtaining SAM files, we mapped, added annotations and normalized all RNA-Seq reads using Partek software (http://www.partek. com/). 29 Using the reference genome of mm10 (mouse) from the UCSC genome browser, 30 22,886 isoforms were mapped to the genome (Fig. 3a) . The expression levels in RNA-Seq were evaluated by detecting the reads per kilobase of exon model per million mapped reads (RPKM) of each gene. By comparing to the expression data of each gene at different days after cocultivation of ESCs and B16-F10 cells, fold changes were calculated. To exclude false-positive data, the RPKM threshold was set at 0.3.
Comprehensive analysis of the RNA-Seq data was conducted to reveal novel alterations of the genome or new insights into the mechanism of apoptosis in B16-F10 cells. According to the strategy aforementioned, we chose and analyzed >2,000 genes among the total of 22,886. We identified >40 genes differentially expressed on Days 0, 3 and 5 after cocultivation. Fas, Casp8, Casp3, bid, FasL, Tnfrsf1a, Ripk1, Mapk14, Foxo3, Ras and other genes were identified as significant. Moreover, apoptosis pathways played important roles during the interaction. For example, Fas was the most significant factor in the network with the most changes in ingenuity pathway analysis (Fig. 3b) .
Fas (fold change [B16-F10 cells on Day 5]/[B16-F10 cells on Day 0] >15; RPKM >0.3) was expressed highly in tumor cells after coculture with ESCs. In addition, expression of all genes in the apoptosis pathway of Fas/Casp8/Casp3 in tumor cells was much higher than on Day 0 after cocultivation (Figs. 3c and 3e ). The upregulation of these genes suggested stimulation of the caspase/proteolytic cell apoptotic pathway that is downstream of the Fas/FasL interaction and directly induces apoptosis. [31] [32] [33] Molecular Cancer Biology At the same time, ESCs started to express FasL to initiate and enhance the apoptosis of tumor cells (Fig. 3d) , suggesting that ESCs may start the ability to induce the apoptosis of tumor cells. We analyzed molecules upstream of FasL in ESCs and found that Ras, Pik3, Mapk8, Mapk14, Smarca4 and ITK were all involved in this complex pathway (Figs. 3c and 3d). According to the RPKM value and the extent of gene changes, Ras-Pik3-Akt signaling pathway was regarded as the most crucial one (Fig. 3c) . Because oncogenic Ras, Pik3 and Akt inhibit the FasL-mediated apoptosis pathway by downregulating expression of Fas or FasL, [34] [35] [36] [37] [38] [39] [40] [41] their low expression in ESCs may provide protection from the overexpression of Fas in tumor cells to induce the Fas/FasL apoptosis pathway in this cocultivation system. Mapk8, Mapk14 and Smarca4 enhance the expression of FasL in ESCs. [42] [43] [44] Thus, their overexpression might improve the apoptosis of tumor cells mediated by ESCs and the Fas/FasL signaling pathway (Fig. 3d) .
Fas/FasL-mediated tumoricidal activity of ESC
Real-time PCR was used to validate the gene expression of Fas, Casp8 and Casp3 in B16-F10 cells and FasL in ESCs after cocultivation. The technology and methods of cell culture, cocultivation and separation were the same as those in the RNA-Seq. During prolonged B16-F10 cell and ESC coculture, mRNA levels of all four genes were increased gradually (Fig. 4) . In ESCs, the mRNA level of the most important gene, FasL, was increased by ninefold on coculture Day 3. Most interestingly, FasL expression increased by 379-fold on Day 5 (p <0.001; Fig. 4a ). Similar to B16-F10 cells, Fas mRNA levels were increased most significantly, by >30-fold on Day 5 vs. Day 0 (Fig. 4b) . Casp8 and Casp3 genes showed the same expression patterns. When we changed B16-F10 cells to Pan02 cells, the same phenomenon was seen (Fig.  S2) . As for protein levels, FAS over expressed on coculture Days 3 and 5, and cleaved CASP8 and CASP3 was seen in tumor cells after coculture with ESCs ( Fig. 4c and Fig. S2c ), indicating activation of this apoptosis pathway.
Apoptosis detection by Annexin V and propidium iodide staining also supported that ESCs induced the apoptosis of tumor cells. Tumor cells were gated using forward scatter and side scatter. Only the homogenous population of B16-F10 cells within our samples was considered. We then defined apoptotic cells as Annexin V positive, and necrotic cells as both Annexin V and propidium iodide positive. We calculated these tumor cells and found that their proportion increased obviously after tumor cells cocultured with ESCs ( Fig. 4d and Fig. S3 ). This result indicated that ESCs played an important role in initiating and enhancing the apoptosis of tumor cells via the Fas/ FasL signaling pathway. Besides, the immunohistochemistry detection of the subcutaneous tumor tissues showed the over expression of FAS and CASP8 in tumor cells, which determined their apoptosis (Fig. 4e) . Thus, ESCs show a great potential in clinical application to tumors. (Fig. 5a ). The features of these two clones were analyzed by PCR and western blotting to confirm the deletion of Fadd in the genome of B16-F10 cells (Figs. 5b and 5c) .
Cells with FADD minus 1,605 bp were applied to coculture with ESCs to determine the importance of the Fas/FasL signaling pathway in the ESC-mediated tumoricidal activity. All technology and methods of cell culture, cocultivation and separation were the same as aforementioned. Because FADD was knocked out, there was no obvious apoptosis in FADD minus 1,605 bp cells after coculture with ESCs, regardless of the coculture ratio or medium (Figs. 6a-6e) . Cleaved CASP3 was not induced in FADD minus 1,605 bp cells, and even total CASP3 was extremely lower than in normal B16-F10 cells (Fig. 6f) . Moreover, the phenomenon was seen in FADD minus 105 bp cells. Therefore, the Fas/FasL signaling pathway was very important for the tumoricidal activity mediated by ESCs. Besides, when we used FasL-inhibitor to inhibit the apoptosis-inducing activity of FasL in ESCs, the apoptotic phenomenon of tumor cells was prevented obviously (Fig.  S4) , which conformed the critical role of Fas-FasL signaling pathway in ESCs mediated tumoricidal activity.
Discussion
ESC-mediated cancer therapy through the Fas/FasL signaling pathway
Cancer is certainly a major disease in humans. It is currently the second leading cause of death in the United States and is expected to surpass heart diseases as the first leading cause of death in the next few years. 45 However, reliable methods to eliminate cancer do not exist. Surgery, chemotherapy, radiotherapy and sometimes immunotherapy (e.g., Herceptin) are methods believed to be useful to some extent, but not absolutely. For some cancers such as melanoma, ineffective apoptotic pathways may contribute to the features of drug resistance and early metastasis. 46 Thus, stimulating apoptotic pathways in tumor cells has become a new trend in cancer treatments. Cells or drugs, which can improve the apoptosis activity in tumor cells, are becoming more important.
Stem cells play critical roles in homeostasis as well as tissue repair and regeneration, but their roles in tumorigenesis are poorly understood. Early studies demonstrate that stem cells have a tumor tropism property, 5, 6 that can be used to deliver anti-tumor drugs and biological agents for cancer therapy. [47] [48] [49] This technique provides an attractive strategy for the treatment of tumors that are inaccessible to conventional therapeutic delivery systems, such as malignant glioma. Mesenchymal stem cells have also been shown to inhibit tumor growth and angiogenesis, implying a new possible treatment for malignant tumor. 9, 50 To further investigate the molecular mechanisms of stem cell and tumor cell interactions, we first confirmed that ESCs inhibited the proliferation of tumor cells both in vitro and in vivo, and then focused on apoptosis pathways identified by RNA-Seq analysis. Based on our results, ESCs enhanced the expression of Fas, Casp8 and Casp3 in tumor cells, while ESCs expressed FasL to induce apoptosis of tumor cells. In a series of probative experiments, Fas, Casp8 and Casp3 were found to have higher expression at both RNA and protein levels in tumor cells, while FasL was expressed at an extremely higher level in ESCs after coculture with tumor cells. These molecular biological analyses clearly verified our findings in the mRNA genomic analysis.
One more finding in our vitro experiments may be that FBs seem to be able to induce the proliferation of tumor cells, since more FBs contribute better growth of tumor cells (Fig. 1) . FBs are one of the most commonly used cells in control studies in many experiments. According to our knowledge, FBs could induce the proliferation of tumor cells since they are full of stromal constituents which could support cell growth. [51] [52] [53] However, this inducement did not affect The Fas/FasL signaling pathway was considered to be crucial in the ESC-mediated tumoricidal activity, and the downstream factors were also clear. In addition, we believed that other FasL-expressing cells in vivo, such as lymphocytes, might also be attracted to improve the apoptosis of tumor cells through the Fas/Casp8/Casp3 signaling pathway. 54 Therefore, stem cells and their induced apoptosis pathways may be a key breakthrough in cancer treatment, which may be a new strategy to treat the disease.
RNA-Seq and the CRISPR/Cas system verify the effect of the Fas/FasL signaling pathway Human ESCs are hard to obtain and too expensive to be widely used in clinical treatment of cancer. Therefore, we performed RNA-Seq to investigate the effect of cocultivating these two kinds of cells, explore the molecular mechanisms of the ESC-mediated tumoricidal activity, and find the targets of ESC-mediated cancer therapy. RNA-Seq analysis allowed us to detect gene expression changes in tumor cells and ESCs in detail. In tumor cells, the gene expression changes were obvious. Genes, such as Fas, TNF, Casp8 and Casp3, which are related to apoptosis pathways, were overexpressed after coculture with ESCs. Fas was at the top in both network and factor rankings in ingenuity pathway analysis because of its significant changes, which is a key factor in ESC-mediated tumoricidal activity.
Since we found Fas is the key factor in tumor cells, the change of FasL expression in ESCs was verified by real-time PCR. However, although FasL in ESCs showed extreme overexpression by >300 times after coculture with tumor cells, it did not appear to have a remarkable rank of gene expression changes in RNA-Seq analysis, which may be due to the expression of many other various genes in ESCs after cocultivation. ESCs were absolutely primary with the most original expression of the genes. Any minute influence would cause a series of changes in gene expression. Therefore, we used Fas in tumor cells for inverse detection to determine the key factor in ESCs.
In our analysis, overexpression of Mapk8, Mapk14 and Smarca4 may be the cause of the overexpression of FasL, while Ras, Pik3 and Akt were downregulated to reduce their influence on inhibiting FasL in ESCs. Thus, we hypothesized that MAP kinase and the JNK family were important to induce FasL in ESC, with facilitation from downregulation of some oncogenes. In addition, Them4 and Ywhaq were considered to be potential-related genes. Because there were so many different genes with the same effects on expression of FasL in different pathways, their general contributions to the activation of FasL in ESCs were noticeable, which also indicates the significance of FasL in ESC-mediated tumoricidal activity.
The CRISPR/Cas9 system is a robust genome editing tool. It employs Cas9 nuclease and a set of sequence-specific CRISPR RNAs that guide Cas9 nuclease to cleave DNA and generate double-strand breaks at target sites, leading to the desired gene insertions, deletions or substitutions at target genome sites. [55] [56] [57] To elucidate that the Fas/FasL signaling pathway plays the most important role in ESC-tumor cell interactions, we used the CRIPSR/Cas9 system to delete the Fadd gene in B16-F10 cells, whose protein is a specific FAS receptor, to demonstrate the significance of the Fas/Casp8/ Casp3 signaling pathway. In consideration of off-target effects of the CRIPSR/Cas9 system, we designed three guide RNAs directed at the functional domain of the FADD protein, to ensure a complete deletion of Fadd gene functions in our experiments.
Clinical application prospect of ESC-mediated tumoricidal activity ESC-mediated tumoricidal activity is significant for cancer therapy. It could be a new method to treat this malignant disease or at least a new concept for cancer treatment. After experimental confirmation of the signaling pathways and key factors in the cellular interaction, we believe that this finding may have a great prospect for clinical application. ESCs could be tracers and killers in tracking, identifying and then killing tumor cells.
We have conceived a "guide protein," produced by ESCs and secreted into the extracellular matrix to induce expression of Fas in tumor cells. This guide protein might be another aspect of ESC-mediated tumoricidal activity, and could be crucial for targeted therapy of cancer in the future. In our RNA-Seq analysis, we detected many changes in ESCs after cocultivation with tumor cells, including some initial differentiation toward immune, cardiovascular, adipose, nervous, skin and skeletal lineages. These changes might contribute to the generation of the exocrine "guide protein" and affect the gene expression in tumor cells.
We are currently investigating this hypothetical guide protein and believe it would be a breakthrough in cancer treatment. With such a protein, apoptosis pathways might be induced in tumor cells in vivo without the use of exogenous ESCs, and lymphocytes with highly expression of FasL would migrate to kill tumor cells as well. We have already some preliminary results, and validation experiments are ongoing. We hope to obtain the "guide protein" to treat cancer and contribute to therapies against this malignant disease.
